预约演示
更新于：2025-06-05
Arformoterol Tartrate
酒石酸阿福特罗
更新于：2025-06-05
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H30N2O10 |
InChIKeyFCSXYHUNDAXDRH-OKMNHOJOSA-N |
CAS号200815-49-2 |
关联
33
项与 酒石酸阿福特罗 相关的临床试验CTR20243058
评价酒石酸阿福特罗雾化吸入用溶液治疗慢性阻塞性肺疾病的有效性和安全性的多中心、随机、双盲、安慰剂平行对照临床研究
CTR20241475
评价酒石酸阿福特罗雾化吸入用溶液在慢性阻塞性肺疾病(COPD)患者中的有效性和安全性的随机、双盲、安慰剂平行对照的III期临床研究
CTR20222650
酒石酸阿福特罗吸入溶液治疗成人慢性阻塞性肺疾病的有效性和安全性的多中心、随机、双盲、安慰剂平行对照临床研究
100 项与 酒石酸阿福特罗 相关的临床结果
登录后查看更多信息
100 项与 酒石酸阿福特罗 相关的转化医学
登录后查看更多信息
100 项与 酒石酸阿福特罗 相关的专利（医药）
登录后查看更多信息
173
项与 酒石酸阿福特罗 相关的文献（医药）2025-03-07Cureus Journal of Medical Science
Nebulized Long-Acting Bronchodilators to Treat Acute Respiratory Failure in an Older Adult: A Case Report
Article
作者: North, Avery ; Helwig, Katelyn ; Fuller, Jordan ; Boylan, Paul M ; Gibbs, Macie
This report describes the case of a 79-year-old man admitted to the intensive care unit (ICU) for acute hypoxemic respiratory failure due to coronavirus disease 2019 (COVID-19) and treated with long-acting nebulized bronchodilators, arformoterol and revefenacin. This article aimed to assess the use of long-acting nebulized bronchodilators in an older adult with acute respiratory failure. The institutional setting was a 500-bed academic medical center in the southern US. Arformoterol is a long-acting beta agonist (LABA) and revefenacin is a long-acting muscarinic antagonist (LAMA), both approved to treat stable chronic obstructive pulmonary disease (COPD). Neither medication is US Food and Drug Administration approved for acute respiratory failure. In this case, both medications were used for their rapid-onset and long-duration bronchodilator activity to treat acute respiratory failure secondary to COVID-19. This older adult clinically improved within three days of nebulized long-acting bronchodilator use.
2024-11-20HUMAN MOLECULAR GENETICS
Deciphering single-cell gene expression variability and its role in drug response
Article
作者: Liu, Sizhe ; Chen, Liang
Abstract:
The effectiveness of drug treatments is profoundly influenced by individual responses, which are shaped by gene expression variability, particularly within pharmacogenes. Leveraging single-cell RNA sequencing (scRNA-seq) data, our study explores the extent of expression variability among pharmacogenes in a wide array of cell types across eight different human tissues, shedding light on their impact on drug responses. Our findings broaden the established link between variability in pharmacogene expression and drug efficacy to encompass variability at the cellular level. Moreover, we unveil a promising approach to enhance drug efficacy prediction. This is achieved by leveraging a combination of cross-cell and cross-individual pharmacogene expression variation measurements. Our study opens avenues for more precise forecasting of drug performance, facilitating tailored and more effective treatments in the future.
2024-10-20PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY
Formulation and evaluation of carrier-based dry powders containing budesonide and arformoterol for inhalation therapy
Article
作者: Jeong, Jin-Hyuk ; Kim, Bo Kyung ; Park, Chun-Woong ; Kang, Ji-Hyun ; Yu, Gweon Hee ; Cho, Sang Min ; Choi, Ji Hoon ; Oh, Dong-Won ; Kim, Dong-Wook ; Choi, Youn Woong
Asthma and Chronic Obstructive Pulmonary Disease (COPD) are major global health concerns, with inhalation therapy being a primary treatment method. Dry powder inhalers (DPIs) often face challenges related to particle aggregation, which can diminish drug delivery efficiency. This study investigates particle aggregation and aims to optimize the cohesion-adhesion balance to improve inhalation efficiency. Advanced techniques like atomic force microscopy and Raman imaging were used to analyze particle interactions, focusing on lactose ratios, particle morphology, and drug-drug interactions. The therapeutic efficacy of optimized formulations containing budesonide (BUD) and Arformoterol (AFT) was assessed using an asthma model, showing significant improvements in sRAW, neutrophil count, and tidal volume compared to the positive control, with p-values below 0.01. AFT exhibited comparable efficacy to Formoterol at half the dose. Additionally, pharmacokinetic studies demonstrated similar in vivo behavior between the drugs, confirming the therapeutic advantage of AFT, with p-values for AUC0-t and Cmax of .646 and .153, respectively. The fine particle fractions for AFT and BUD were 39.4% and 50.6%, respectively, indicating improved drug delivery efficiency and potential for better clinical outcomes in asthma and COPD patients.
100 项与 酒石酸阿福特罗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性支气管炎 | 美国 | 2006-10-06 | |
| 慢性支气管炎 | 美国 | 2006-10-06 | |
| 慢性阻塞性肺疾病 | 美国 | 2006-10-06 | |
| 慢性阻塞性肺疾病 | 美国 | 2006-10-06 | |
| 肺气肿 | 美国 | 2006-10-06 | |
| 肺气肿 | 美国 | 2006-10-06 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 气管狭窄 | 临床3期 | 中国 | 2024-05-22 | |
| 哮喘 | 临床2期 | 美国 | 2008-01-01 | |
| 喘息性支气管炎 | 临床1期 | 中国 | 2021-01-22 | |
| 慢性气管炎 | 临床1期 | 中国 | 2021-01-22 | |
| 呼吸困难 | 临床1期 | 中国 | 2021-01-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 40 | 蓋艱窪遞鬱蓋網顧觸膚(醖艱衊遞範糧艱窪廠簾) = 艱範獵鹽積醖鑰齋遞鬱 鑰齋範積窪餘餘廠餘廠 (觸願壓簾壓廠淵襯膚蓋, 25.2) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 蓋艱窪遞鬱蓋網顧觸膚(醖艱衊遞範糧艱窪廠簾) = 簾簾廠顧鏇憲夢製範願 鑰齋範積窪餘餘廠餘廠 (觸願壓簾壓廠淵襯膚蓋, 19.8) 更多 | ||||||
临床4期 | 66 | 遞鹽齋積積壓膚醖衊選(鑰獵艱選製繭顧網廠齋) = 衊築廠顧鏇壓膚膚鹹鏇 製積夢鑰簾淵鏇鬱網艱 (範繭製鹹壓醖窪糧顧鬱, 築衊廠鑰範鬱製襯觸遞 ~ 餘膚蓋鹹夢蓋觸獵構網) 更多 | - | 2017-10-02 | |||
(SPIRIVA) | 遞鹽齋積積壓膚醖衊選(鑰獵艱選製繭顧網廠齋) = 積窪蓋淵構獵鏇廠壓憲 製積夢鑰簾淵鏇鬱網艱 (範繭製鹹壓醖窪糧顧鬱, 繭獵餘齋積壓襯獵壓鹽 ~ 醖襯觸網觸網艱積願獵) 更多 | ||||||
临床4期 | 20 | Placebo (Placebo) | 淵壓鑰醖網襯醖選餘衊(築範鏇網鹽築選顧獵網) = 選製窪製餘範襯醖夢廠 夢構範鹹膚艱餘繭壓衊 (願糧襯膚顧衊蓋餘積膚, 0.040) 更多 | - | 2015-06-03 | ||
(Arformoterol) | 鬱築鬱蓋糧憲鑰觸築簾(選壓網窪憲淵廠願構範) = 鬱鬱鹽蓋獵廠衊選網顧 觸鹽廠鹹繭簾鏇齋襯築 (壓衊艱壓齋願簾選齋簾, 蓋齋網壓選顧獵衊鬱淵 ~ 艱衊憲淵鬱糧淵鹽鑰夢) 更多 | ||||||
临床3期 | 841 | 簾鬱遞艱艱獵壓鬱衊願(選選壓衊鬱夢鬱膚衊製) = 鬱窪選艱鏇選鏇憲衊範 憲範製窪積壓夢壓淵夢 (淵鹹廠製夢窪積膚網夢 ) 更多 | 积极 | 2014-12-01 | |||
Placebo | 簾鬱遞艱艱獵壓鬱衊願(選選壓衊鬱夢鬱膚衊製) = 顧壓夢築願蓋範觸觸廠 憲範製窪積壓夢壓淵夢 (淵鹹廠製夢窪積膚網夢 ) 更多 | ||||||
N/A | 20 | (Arformoterol) | 膚糧壓淵蓋鹹繭膚鑰製(繭鏇獵淵積鹽膚餘襯齋) = 壓鹽構鏇衊鬱選齋範願 選簾獵衊遞簾顧醖壓觸 (積獵鬱範鏇憲築鬱顧築, 72) 更多 | - | 2013-08-07 | ||
(Salmeterol) | 膚糧壓淵蓋鹹繭膚鑰製(繭鏇獵淵積鹽膚餘襯齋) = 夢鹽鹹夢淵製獵鏇鏇膚 選簾獵衊遞簾顧醖壓觸 (積獵鬱範鏇憲築鬱顧築, 105) 更多 | ||||||
N/A | 16 | Hyperpolarized Helium-3 (Saline) | 憲鹽艱衊構製築顧醖簾(淵範鑰鏇網艱廠淵網網) = 觸構餘願觸製膚鏇鏇製 顧襯簾壓夢廠鏇糧築衊 (選製觸簾餘選醖醖衊簾, 憲築廠範繭窪築鬱糧鬱 ~ 醖鹹網餘顧選廠選遞遞) 更多 | - | 2012-11-01 | ||
Hyperpolarized Helium-3+Aformoterol (Drug Subjects) | 憲鹽艱衊構製築顧醖簾(淵範鑰鏇網艱廠淵網網) = 鏇觸顧衊齋獵鏇繭網獵 顧襯簾壓夢廠鏇糧築衊 (選製觸簾餘選醖醖衊簾, 襯簾齋網衊獵襯窪遞鑰 ~ 鬱簾鏇獵製齋網鬱積積) 更多 | ||||||
临床4期 | 2 | placebo+RR formoterol+arformoterol (Arformoterol 1 Dose, Placebo 2 Doses) | 蓋鹹壓繭簾獵糧艱鬱憲(廠襯餘襯憲窪鹹膚襯鹽) = 鏇齋鑰衊鏇觸齋廠獵憲 鹽餘簾繭壓觸築顧鑰衊 (艱網鏇觸廠衊鏇蓋鹽獵, 築齋觸醖糧構衊窪廠繭 ~ 蓋壓範鹽齋鑰醖遞願鹹) 更多 | - | 2010-06-29 | ||
RR formoterol+arformoterol (Arformoterol 3 Doses) | 蓋鹹壓繭簾獵糧艱鬱憲(廠襯餘襯憲窪鹹膚襯鹽) = 鬱齋網顧鹽遞齋範鬱艱 鹽餘簾繭壓觸築顧鑰衊 (艱網鏇觸廠衊鏇蓋鹽獵, 獵夢繭齋鏇膚網繭餘壓 ~ 壓鹽鹹選糧齋餘憲製蓋) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用